PRESTIGE BIOPHARMA
PRESTIGE BIOPHARMA IDC
PRESTIGE BIOLOGICS
Beyond technological discovery, expanding access to care for patients around the world
Innovative Drug
Development of First-in-Class therapeutics for unmet diseases
Biosimilar
Prominent Biosimilars pipelines for accelerating market access
Platform Technology
A drug delivery platform that enhances treatment convenience
Diagnostics
Diagnostics for Pancreatic cancer by detecting PAUF
Prestige Biopharma Attracts Over 300 Companies to Its Booth at CPHI
Prestige Biopharma Attracts Over 300 Companies to Its Booth at CPHI
Prestige Biopharma Group announced on the 7th that more than 300 companies visited its standalone booth during CPHI 2022 (Convention on Pharmaceutical Ingredients), one of the world’s largest pharmaceutical and biotechnology exhibitions, held from November 1 to 3.
During the three-day event, over 300 companies and approximately 700 industry professionals visited the company’s booth. Visitors showed strong interest in the group’s key pipeline programs as well as the CDMO capabilities of Prestige Biologics, which are supported by large-scale manufacturing facilities.
The company noted that it received significant attention from industry participants, particularly due to its integrated value chain covering the entire process from drug development to manufacturing.
Jaeyoung Yang, Head of Business Development at Prestige Biologics, stated, “This exhibition marked the official European debut of Prestige Biologics as a CDMO company. We plan to analyze the information collected from booth visitors and meeting discussions to provide tailored services based on customer segments.”
Reference: SBS Biz (https://biz.sbs.co.kr)
Read Prestige news >>
